Last reviewed · How we verify
VXM01
At a glance
| Generic name | VXM01 |
|---|---|
| Also known as | Investigational VEGFR-2 DNA Vaccine |
| Sponsor | Vaximm GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma (PHASE1, PHASE2)
- VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma (PHASE1)
- VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis (PHASE1)
- VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VXM01 CI brief — competitive landscape report
- VXM01 updates RSS · CI watch RSS
- Vaximm GmbH portfolio CI